Early Phase 1 results from 15 adults with difficult-to-treat lipid disorders have shown that CTX310 – a one-time CRISPR-Cas9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback